Pioneering studies in pancreatic cancer patients revealed that anti-CD40 agonistic antibodies not only stimulate macrophage-mediated tumor cell engulfment but also enhance dendritic cell (DC) cross-presentation and T-cell priming (90). Here, CD40 is linked to neoplasm.